Over the past 32 years ChemDiv has successfully completed hundreds of leads, candidates and new drug programs to treat cancer, neurological, infectious, cardiometabolic and immune diseases with pharma, biotech and academic partners around the globe. We are revolutionizing the field of drug discovery by harnessing the power of Hybrid Artificial Intelligence (AI) /Machine Learning (ML) which is curated by our scientists at each step in the process.
Focused and targeted libraries
114 predesigned screening libraries. Introduced by therapeutical areas, targets and mechanism of action.
Active Reference Sets
17 annotated libraries. Over 220,000 compounds with available bioactivity data, >25,000 targets, >1,000,000 activity data points across various areas.
Diversity libraries
Representative diversity sets cover space of billions compounds. 2D and 3D.
Preplated libraries
Represents 30B virtual space of drug-like and lead-like compounds, Сompounds passed REOS and PAINS, have optimized solubility and «target diversity» approach, Compounds from over 70 targeted and focused libraries, Cherry-pick by plates
Inhibitors and Approved Drugs
Small Molecule Inhibitors, >Approved drugs/ Repurposing
Building blocks
Search and purchase
Substructure Search for Screening Compounds
Search and purchase in the largest commercially available space. Regular new arrivals.
Inhibitors and Approved Drugs
Download database
1.6M Screening compounds, 70K Building blocks, 45K Inhibitors & drugs
30+
years of industrial experience
47
approved drugs
2700+
satisfied customers
5
R&D hubs worldwide
Popular
Integrated drug discovery services
In silico drug design (CADD)
Discovery biology
Medicinal chemistry
Preplated diverse 600K layered set
600,000 compounds
CNS BBB Library
23,432 compounds
Complete Stock Database of Drugs and Inhibitors
45214 compounds
Repurposing Library
4541 compounds
Off patent drugs (OFP)
804 compounds
Anticancer Library
65,000 compounds
IMiD small molecule library
2000 compounds
FDA Approved Drugs
1891 compounds
#BIO2024!
#BIO2024!
Thank you to everyone who visited us at the ChemDiv, Inc. booth in the California Pavilion.
Thank you to everyone who visited us at the ChemDiv, Inc. booth in the California Pavilion.
Novel Potent TIM-3 Inhibitors were discovered in ChemDiv’s collection.
The ChemDiv’s proprietary library of chemically diverse small molecule compounds was demonstrated to be a source of selective inhibitors targeting specific check points was found out in a recen...
ChemDiv Company in publications and patents
We are passionate about the latest trends in life sciences and medicinal chemistry and closely monitoring the latest developments and discoveries in this area.
It means a lot to us if our custome...
New therapy from UI Health
New therapy from UI Health becomes the first FDA-approved treatment for brittle type 1 diabetes
Science & Nature Reviews, February 2022. Part II
Neurophysiology
Kelava, I., Chiaradia, I., Pellegrini, L. et al. Androgens increase excitatory neurogenic potential in human brain organoids. Nature 602, 112–116 (2022)
Sex-based brain dif...
Beyond binary: scaled molecular fingerprints for maximum diversity picking
Tags
Custom ChemistryNovel Scaffolds and Discovery LibrariesCustom Building Blocks for DNA Encoded LibrariesScale up SynthesisMacrocycle CompoundsIn silico Drug Design (CADD)PROTACADME, DMPKMedicinal ChemistryDNA Encoded Libraries-CDI-CapabilitiesDiscovery BiologyAssay DevelopmentHigh Throughput Screening (HTS)Animal ModelsToxicology and SafetyChemistry, Manufacturing and ControlsPre-Plated SetRepresentative CompoundsNatural-Product3D-PharmacophoreMCE-18RepresentativeSoluble DiversityTargeted DiversitySmartTMAntiviralGPCR3DPhenotypic ScreeningCNS activityTranscription FactorsDrugs LibraryTarget ActivityTherapeutical DiversityCNSIon ChannelsProteases HumanKinases HumanPhosphatases HumanReceptors HumanOpportunistic PathogensCancerCardiovascularMetabolicImmune systemInfectionsMusculoskeletalDigestive systemRespiratory tractOtorhinolaryngologicNervous systemEyeMaleFemaleHemic and lymphaticCongenitalSkinEndocrineAnimalWoundsKinasesProteasesPhosphatasesNuclear receptorsOthersPPI modulatorsReceptor's ligandsEpigeneticMimeticsCyclic compoundsFragmentsPoolChemical classes AgroAllosteric Inhibitors
Event Calendar
November 24 2024. Discovery US 2024
December 7–10 2024. ASH Annual Meeting
January 25–29 2025. SLAS2025
March 23–27 2025. ACS Spring 2025
April 1–4 2025. Drug Discovery Chemistry
April 23–24 2025. Festival of Biologics San Diego 2025
April 28–29 2025. Stanford Drug Discovery Symposium